Platelet Concentrate Treatments for Temporomandibular Disorders: A Systematic Review and Meta-analysis

Abstract

Objectives: This systematic review compared platelet concentrates (PCs) versus hyaluronic acid (HA) or saline/Ringer’s solution injections as treatments of temporomandibular osteoarthritis and disc displacement in terms of pain and maximum mouth opening (MMO). Methods: PubMed, Cochrane, and Scopus were searched up to March 6, 2020. Inclusion criteria were randomized clinical trials (RCTs). Exclusion criteria were case series, observational studies, animal studies, and reviews. The Effective Public Health Practice Project (EPHPP) quality assessment tool was used to assess the risk of bias in the included studies. The weighted mean difference was used to compare the results. Results: Nine RCTs were included with a total of 407 patients. The numbers of joints treated were 262, 112, and 112 in the PC, HA, and saline groups, respectively. The quality of studies was rated as strong in 4 studies, moderate in 4 studies, and weak in 1 study. The meta-analysis revealed that PCs decreased pain visual analogue scale (VAS) scores compared to HA by an average of −1.11 (CI, −1.62 to −0.60; P < 0.0001) and −0.57 (CI, −1.55 to 0.41; P = 0.26) at 3 and 12 mo follow-up respectively. Also, the average decrease in pain scores with PC compared to saline was −1.33 (CI, −2.61 to −0.06; P = 0.04), −2.07 (CI, −3.46 to −0.69; P = 0.003), and −2.71 (CI, −4.69 to −0.72; P = 0.008) at 3, 6, and 12 mo, respectively. Regarding MMO measurements, PC was comparable to HA, but it was significantly better than saline after 3 and 6 mo [2.9 mm (CI,1.47 to 4.3; P < 0.0001), and 1.69 mm (CI, 0.13 to 3.25; P = 0.03) respectively]. Conclusion: PC reduces pain VAS scores compared to HA during the first 3 m after treatment, and when compared to saline, it reduces pain and increases MMO for longer durations. However, due to differences between groups regarding PC preparation protocols and study heterogeneity, further standardized RCTs are required. Knowledge Transfer Statement: This study provides researchers and clinicians with quantitative and qualitative analyses of the current evidence regarding the clinical outcomes of platelet concentrate injections in the treatment of temporomandibular joint osteoarthritis and disc displacement in terms of pain control and maximum mouth opening.

Treatment of Mandibular Hypomobility by Injections into the Temporomandibular Joints: A Systematic Review of the Substances Used

“…There are many known complications of steroid administration, including edema, hypoaesthesia, skin hypopogmentation and even skin atrophy [16,17]. In recent years, injections of platelet-rich plasma (PRP) into the TMJ cavities have become popular and found to be effective [7,[18][19][20][21][22]. Apart from autologous PRP, other self-derived blood products are also used: plasma rich in growth factors (PRGF) and injectable platelet-rich fibrin (I-PRF) [7,23].…”

Evaluating the role of intra articular injection of platelet‐rich fibrin in the management of temporomandibular joint osteoarthritis: A STROBE compliant retrospective study

“…With regard to MMO there was no significant difference between PRP and control group. Al-Hamed et al 17 in their meta-analysis showed significant reduction in pain scores with PCs and increase in mouth opening. PCs cause immunomodulation.…”

Mechanisms of Action and Efficacy of Hyaluronic Acid, Corticosteroids and Platelet-Rich Plasma in the Treatment of Temporomandibular Joint Osteoarthritis—A Systematic Review

“…PRP is an autologous concentrate of platelets and growth factors, derived from centrifugated blood [ 52 , 53 , 54 ]. There have been listed in the literature two other types of platelet concentrates, namely platelet-rich fibrin (PRF) and plasma rich in growth factors (PRGF) [ 55 ]. PRP may be obtained only from the liquid blood.…”